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Introduction
A growing body of evidence suggests that angiotensin II (Ang II)' can modulate vascular smooth muscle cell (VSMC) growth (1) (2) (3) . Ang II induces VSMC hypertrophy, but not hyperplasia in confluent quiescent cells in a defined serum-free medium ( 1 ). Our laboratory has demonstrated further that the Ang II-induced hypertrophy is associated with increased 1. Abbreviations used in thispaper: Ang II, angiotensin II; PDGF, platelet-derived growth factor; PKC, protein kinase C; TGFj#1, transforming growth factor-#,(; TGFAB, anti-TGFj31 neutralizing antibody; VSMC, vascular smooth muscle cell. mRNA levels of protooncogenes, c-fos, c-myc, and c-jun, and the increased expression and secretion of the autocrine growth factor platelet-derived growth factor (PDGF) AA homodimer (4, 5) .
PDGF has been reported to be a potent mitogen and, therefore, the autocrine secretion of PDGF was expected to stimulate VSMC hyperplasia. However, recent experiments in our laboratory that utilize antibodies and antisense oligonucleotides directed against PDGF AA have demonstrated that autocrine PDGF AA is an important mediator of AngII-stimulated VSMC hypertrophy (6) . This paradoxical response of hypertrophy but not mitogenesis led us to postulate that Ang II may be a bifunctional growth modulator of VSMCs by activating both proliferative and antiproliferative cellular events. Indeed, recent studies in our laboratory have demonstrated that prolonged exposure to Ang II inhibited basic fibroblast growth factor-induced DNA synthesis (7) . Moreover, the Ang II inhibitory effect was mimicked by a protein kinase C (PKC) activator and blocked by down-regulation of the PKC pathway (7) . These findings suggest that Ang II can activate an antiproliferative effect that is mediated by PKC.
Recently, transforming growth factor-#,( (TGF(,3) has been reported to exert a bifunctional effect on VSMC growth (8) (9) (10) (11) (12) . Similar to observations with Ang II, administration of TGFj3l stimulates VSMC hypertrophy and inhibits mitogenstimulated DNA synthesis (8) . The autocrine production of biologically active TGF#, in VSMCs has not been previously demonstrated. In the present study, we tested the hypothesis that the growth modulatory effects of Ang II may be mediated by the activation of autocrine production of TGFj31. Our results support the postulate that Ang II is a bifunctional growth factor that activates both proliferative and antiproliferative pathways. The autocrine production of biologically active TGF#1 is a major determinant of whether VSMCs grow by hypertrophy or hyperplasia. Inactivation of this antiproliferative autocrine growth factor unmasks the full mitogenic effect of Ang II. These findings may have implications for the role of Ang II as a determinant of vascular structure.
Methods
Cell culture. Primary cultures of VSMCs were initiated by enzymatic dissociation from the aortae of 7-8-wk-old male Sprague Dawley rats (Charles River Breeding Laboratories, Wilmington, MA) by the method ofOwens et al. ( 12 ) . VSMCs were maintained in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 (DME/F12) (Gibco Laboratories, Grand Island, NY), 10% heat-inactivated fetal calf serum (FCS) (Gibco), penicillin ( 100 U/ml), streptomycin ( 100 Ag/ml), 25 mM Hepes buffer, glutamine, and glucose. Cells were incubated at 37°C in a humidified atmosphere of 95% air/5% CO2. The medium was changed every two days and cells passaged by trypsin/ EDTA with a split ratio of 1:10 in 75-cm2 flasks (Costar, Cambridge, MA).
Utilizing this technique, VSMCs exhibit typical, spindle-shaped morphology and a multilayered growth pattern, contain myofilaments by electron microscopy, and express a-actin as demonstrated by immunofluorescence studies with a smooth muscle specific anti-a-actin antibody (Sigma Chemical Co., St. Louis, MO). Studies were conducted on VSMCs (passages 7-12) that had achieved confluence for two days in 10% FCS/DME/F12. The cells were then incubated in a defined serum-free medium (DME/F12 plus insulin [ (15) (16) (17) . Extensive experimental characterization has documented the ability ofthe antibody to block specifically the TGFB,-induced stimulation of anchorage-independent growth of rabbit kidney cells ( 15); inhibition of mink lung epithelium ( 16, 18) , and VSMC growth ( 18); stimulation of fibroblast ( 19) and monocyte migration (20) ; and inhibition of endothelial cell migration (21 ) . The capacity of the TGFAB to neutralize TGFfl-induced inhibition of mink lung epithelial cell growth was also determined specifically in this study. The effect of the TGFAB was assessed by preincubation of the antibody for 1 h with the ligand before exposure to the mink lung The possible involvement of PKC activation as a mediator of the Ang II effect was examined by incubating VSMCs acutely with the PKC activator, phorbol myristate acetate (PMA) ( 10 ng/ml) and the effect of TGFt,1 mRNA expression was examined. In addition, several investigators have established that prolonged PMA (100 ng/ml) pretreatment for 24 h blocks PKC activation in VSMC (21) (22) (23) (24) (25) . We therefore employed this protocol to assess the effect of down-regulating the PKC pathway on the response to the acute administration of Ang II and PMA on TGF#, gene expression.
Metabolic studies were conducted with radiolabeled precursors to characterize the growth response to Ang II. DNA synthesis was assessed by administering tritiated thymidine (2 MCi/ml) for a period of 24 h beginning 12 h after Ang II stimulation. Protein synthesis was measured by incubating cells with tritiated proline ( 10 uCi/ml) for a 4-h period beginning 15 h after Ang II stimulation. Preliminary experiments demonstrated that these incubation time periods correspond to periods of maximal incorporation of these radiolabeled precursors. At the end of the incubation period, the medium was removed, the cells washed twice with PBS, then washed once with 10% TCA, followed by incubation with 10% TCA for 30 min at 4°C. The TCA insoluble material was washed twice with ethanol, solubilized in 0.25 M NaOH, and then buffered to neutral pH. Tritiated thymidine and proline incorporation was determined by liquid scintillation spectrometry of a 50-i1 aliquot.
We tested the hypothesis that TGF#,B modulates the Ang II-induced growth response by assessing the effect of the TGFAB ( 100 ug/ ml) compared to an equal concentration of control IgG on the rate of protein and DNA synthesis and cell proliferation. Incubation with the TGFAB in the presence ofvehicle induced a modest increase in thymidine incorporation compared to control IgG under basal conditions (see Results). In order to more closely examine the direct effect ofAng II stimulation, the data are also expressed as the difference between the Ang II-stimulated cells and vehicle-treated cells for each antibody group. Ang II's stimulatory effect on thymidine or proline uptake is expressed as the difference in counts per minute between Ang II-stimulated cells and the vehicle-treated control in the presence ofeither control IgG ( 100 ug/ml) or the TGFAB ( 100 Mg/ml). To confirm that the potentiated growth response to co-incubation with Ang II and TGFAB was related to selective neutralization of active TGFIB, we preincubated the TGFAB ( 100 ,g/iml) with TGFB, ( 1 ng/ml) before administration into the culture medium. The effect of coincubation of Ang II with the TGFAB prebound to TGF#, on DNA synthesis was compared to the response to coincubation ofAng II with TGFAB alone or control IgG. The data is expressed as the difference in counts per minute between Ang II-stimulated cells and the vehicle-treated control in the presence ofcontrol IgG, the TGFAB alone, or TGFB, prebound to the TGFAB. Furthermore, to assess the specificity of the effect of co-incubation ofwith the TGFAB on DNA synthesis, we examined the growth response to submaximal concentrations of basic fibroblast growth factor ( 10 ng/ml) in the presence ofcontrol IgG ( 100 Mg/iml) vs. TGFAB (100 Ag/ml) (n = 16). To confirm that changes in thymidine incorporation were associated with mitogenesis (cell division with an increase in cell number), the effect ofTGFAB on Ang Il-induced cell prolifera- 
Results
Confluent, quiescent adult rat aortic VSMCs exhibited low levels of constituitive TGF31 mRNA expression. Incubation with Ang II resulted in a four-to eightfold increase in mRNA levels (Fig. 1, top) . This response was detectable within 4 h ofincubation and was sustained for at least 20 h. The response was dose dependent with a threshold of -10-9 M.
It is well established that PKC is an important mediator of cellular events stimulated by Ang II. Indeed, previous experiments have suggested that Ang II can produce an antiproliferative effect via a PKC-dependent pathway (7). We, therefore, examined the role of PKC as a mediator of Ang II-induced TGFj31 gene expression. Utilizing the protein kinase activator, PMA, we were able to demonstrate increases in TGF31 mRNA levels similar to that achieved with Ang II. The inactive phorbol ester, 4-a phorbol didecanote had no effect on TGFB1 expression (Fig. 1, bottom) . To further assess the role of PKC activation as a mediator of the Ang II effect on TGF,3j mRNA expression, we inactivated this pathway by a 24-h pretreatment with PMA. Down-regulation of the PKC pathway was confirmed by demonstrating that acute PMA incubation had no significant effect on TGF31 mRNA levels. Indeed, 24-h PMA pretreatment blocked the stimulatory effect of Ang II on TGF31 gene expression (Fig. 1, bottom) .
In order to assess whether the Ang II effect on TGF31 (Fig. 3, top) .
In order to assess the role ofautocrine TGF#I as a modulator of Ang II-induced VSMC growth, we examined the effect of co-incubation with TGFAB. This antibody blocked the inhibitory effect of purified TGF#, on mink lung epithelial cell growth (Fig. 3, bottom) (Fig. 4, top) . To further confirm the specificity ofthe action of the TGFAB, we assessed its effect on growth factor's mitogenic action. TGFAB had no effect on 10 ng/ml basic fibroblast growth factor-stimulated thymidine incorporation in VSMC as compared with coincubation of basic fibroblast growth factor with the IgG control (6,504+505 vs. 5,908±249 cpm; P > 0.05).
In accordance with the thymidine incorporation data, Ang II induced a 50% increase in cell number in the presence of TGFAB (P < 0.01 ) (Fig. 4, bottom) . In contrast, Ang II had no significant stimulatory effect on cell proliferation during coincubation with IgG as previously shown. Thus, blockade of autocrine TGF(31 activity unmasked Ang II-induced mitogenesis. TGF-beta 1 (pg/ml) perplasia in serum-free media. We postulated that Ang II has a bifunctional effect on VSMC growth. Ang TI may activate in VSMC a proliferative pathway (PDGF), as well as an antipro-* liferative pathway, such that the net effect is hypertrophy without hyperplasia. Several studies have documented that the administration of TGF31 to VSMC induces cellular hypertrophy and inhibits mitogen stimulated proliferation (8, 9, 1 1 ). We were intrigued by the observation that TGF,31 has bifunctional effects on VSMC growth similar to that induced by Ang II. Accordingly, we pos- (29) . Moreover, we observed that coincubation of basic fibroblast growth factor with the TGFAB failed to potentiate the mitogenic effect of this peptide. Preliminary data suggests that in contrast to Ang II, basic fibroblast growth factor fails to induce the production of biologically active TGFf,3 (30) . Hence, the potentiation ofDNA synthesis by the TGFAB is due to specific antagonism of the effect of active TGF,31 generated by the VSMC. These data suggest that Ang II stimulates the production of biologically active TGFI31 which, in turn, exerts an antiproliferative influence on the growth stimulatory effects of Ang II. Consequently, the net growth response to Ang II is hypertrophy without hyperplasia. However Given that several cell types secrete a latent form ofTGF,)1 (17) , it is interesting to note that Ang II can release a biologically active form of the protein from VSMC. The mechanism of activation of the TGF,31 precursor to the active form under these conditions is unknown at this time. The serine protease plasmin converts the latent TGFB1 to its active form in vitro ( 16) . Recently, it has been demonstrated that the precursor of plasmin, plasminogen, binds to the extracellular matrix (31 ) and that Ang II stimulates plasminogen activator production by cultured vascular smooth muscle cells (32) . We speculate that Ang II-induced generation of plasmin may result in the proteolytic activation of latent TGF#I3.
In conclusion, we have established that Ang II has a bifunctional effect on VSMC growth (7). We have documented that Ang II activates a proliferative, as well as an antiproliferative pathway. Ang II's bifunctional properties result in the capacity to induce VSMC hypertrophy or hyperplasia, depending on the cellular milieu. The induction ofbiologically active TGF(#1 is a major determinant of whether the cell undergoes hypertrophy or hyperplasia. It is interesting to speculate that under certain pathological conditions (e.g., endothelial injury and/or mitogen stimulation), this antiproliferative pathway may be inactivated. This postulate may explain the observations that Ang II may promote VSMC mitogenesis in the presence of serum in vitro (3, 18) or in response to vascular injury in vivo (2) . Thus, the balance of autocrine proliferative and antiproliferative factors can modulate the growth response to vasoactive substances. These findings are consistent with the concept that vasoactive substances may participate in the process of structural remodeling within the vasculature in diseases such as hypertension and arteriosclerosis.
